You are here
Prostate
Prostate knowledge base with publications, presentations, videos and more.
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
Clin Cancer Res. 2015 Feb 15;21(4):795-807
03/12/2015Comment from Henk van der Poel: Loss of Rb associated with increased sensitivity of PCA cell-lines to cabazitaxel. LNCaP and C4-2 cell lines are more sensitive to cabazitaxel than docetaxel. The later comparison is currently clinically being tested in the FIRSTANA phase III trial in men with CRPC.
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer
02/23/2015Comment from Henk van der Poel: Most crucial question: are patients that opt for active surveillance at increased risk of progression after local treatment for their prostate cancer? The different criteria used for prediction of inclusion and progression in 26 studies resulted in an active treatment rate of 1-22% per person year. Indications for change to active treatment were ranged, but at forest plot analysis rebiopsy gleason grade was the most frequently reported indication for active treatment in almost 40%. Follow up was short (<5y) which suggests that the observed upgrading is more due to undersampling than biological progression.
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Lancet. 2014 Dec 6;384(9959):2027-35.
02/17/2015Comment from Henk van der Poel: Statistically speaking, to prevent one prostate cancer death at 13 year follow up, 781 men have to be invited for screening and 27 have to be diagnosed with prostate cancer. Clearly, with growing follow up the benefit of screening on survival increases. It is time we contemplate on how large the absolute benefit of screening should be to stop banning it.
Predicting survival after whole-brain irradiation for cerebral metastases from prostate cancer
Anticancer Res. 2014 Aug;34(8):4357-60.
02/12/2015Comment from Henk van der Poel: How to treat men with brain-metastasized disease based on overall survival scores? This score may help to decide on the extent of radiotherapy based on life-expectancy after 6 months.
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer
Invest New Drugs. 2014 Dec 3. [Epub ahead of print]
02/12/2015Comment from Henk van der Poel: In less than 1% seizures may occur after enzalutamide use. PRES (seizure, headache, impaired vision and hypertension) should be recognized by oncologists and was shown to be reversible in this case.
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens
Clin Cancer Res. 2014 Dec 15;20(24):6269-76
02/06/2015Comment from Henk van der Poel: The observation that abiraterone is less effective after ketoconazole (51% more than 30% PSA decrease) is not surprising but the fact that men with higher serum DHEA levels may still respond is promising and may be helpful to select men with CYP17 inhibitory medication in combination with ARV7 expression.
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells
J Urol. 2015 Feb;193(2):690-8
02/06/2015Comment from Henk van der Poel: Androgen receptor splice variants were found predictive of prognosis in men treated with enzalutamide and abiraterone (Antonarakis et al., NEJM 371:1028, 2014). In the study by Nacusi et al., a set of genes was identified that was regulated by a specific AR splice variant but not by full-length AR. Interestingly, these ARV targeted genes were also associated with prostate cancer and metastasized disease. A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost
Radiother Oncol. 2014 Dec;113(3):404-9. doi:
02/06/2015Comment from Henk van der Poel: Brachy boost for radiotherapy of prostate cancer resulted in worse bowel, urinary and sexual function outcome compared to stereotactive radiotherapy in 84 men. Long term oncological outcome comparison data are needed. Brachy boost for radiotherapy of prostate cancer resulted in worse bowel, urinary and sexual function outcome compared to stereotactive radiotherapy in 84 men. Long term oncological outcome comparison data are needed.
Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: Results of a first feasibility and case control study
Urologe A. 2014 Dec 19. [Epub ahead of print]
01/26/2015Comment from Henk van der Poel: In 23 men with less than 4 bone metastases, prostatectomy after a good response to neoadjuvant androgen ablation resulted in a longer interval to CRPC development, (40m versus 29m) in comparison to a selected control group only treated with androgen ablation. Overall survival of both groups was similar but local problems seemed less in the prostatectomy group. Functional QOL data were not extensively reported but these data hold promise and warrant a randomized trial. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer
Biomed Res Int. 2014;2014:501213
01/26/2015Cooment from Henk van der Poel: Although timely, the topic of local therapy in metastasized prostate cancer is not without discussion. Incidental reports showed rapid metastases progression after local (surgical) therapy (Ceelen et al., Crit Rev Oncol Hematol. 2014 Jan;89(1):16-26). The review by Aoun and Velthoven warns against expectations of cure in treating men with metastasized PCA. Careful analysis in comparative studies seems mandatory before uninformed widespread use is advocated.
Pages
Prostate Cancer News from ASCO 2014
Commentaries from Susanne Osanto on a selection of presentations within Prostate Cancer from this year’s ASCO meeting.
Latest Updates from the Advance Prostate Cancer Resource Centre
Invalid RSS Feed
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.